TABLE 1

Pharmacokinetic parameters of E2074 in rats, dogs, and monkeys

The pharmacokinetic parameters represent the mean ± S.E. of three animals or five rats, or the mean of two monkeys.

RatDogMonkey
i.v.OralOralOrali.v.OralOrali.v.OralOral
Dose (mg/kg)13103013101310
tmax (h)NA0.25–0.5a0.250.25–0.5NA0.5–1.00.5–1.0NA2b1–2
Cmax (µg/ml)NA0.02 ± 0.01a0.20 ± 0.031.36 ± 0.49NA0.02 ± 0.011.07 ± 0.27NA0.04b0.47 ± 0.06
t1/2 (h)0.85 ± 0.020.50 ± 0.02a0.57 ± 0.031.36 ± 0.331.04 ± 0.020.91 ± 0.161.82 ± 0.353.18 ± 0.925.42b2.95 ± 0.60
AUC (µg·h/ml)0.31 ± 0.010.02 ± 0.01a0.17 ± 0.021.42 ± 0.460.62 ± 0.110.02 ± 0.012.73 ± 1.230.76 ± 0.090.18b1.58 ± 0.15
CL (l/h/kg)3.21 ± 0.12NANANA1.70 ± 0.26NANA1.35 ± 0.14NANA
Vss (l/kg)2.54 ± 0.08NANANA1.84 ± 0.32NANA3.98 ± 0.30NANA
BA (%)NA2.65.315.1NA1.243.7NA7.820.9
  • AUC, area under the plasma concentration curve; BA, bioavailability; CL, clearance; E2074, 2-[(2R)-2-fluoro-3-{(3r)-[(3-fluorobenzyl)oxy]-8-azabicyclo[3.2.1]oct-8-yl}propyl]-4,5-dimethyl-2,4-dihydro-3H-1,2,4-triazol-3-one; NA, not applicable; t1/2, half-life; tmax, time to reach Cmax; Vss, steady-state volume of distribution.

  • a Mean ± S.E. of three animals or five rats.

  • b Mean of two monkeys.